CLSN Celsion Corp

Celsion Corp is a fully-integrated oncology drug development company. The Company is engaged in developing a portfolio of cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies.

$1.96  0.00 (0.00%)
As of 09/20/2022 16:00:00 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  08/01/2001
Outstanding shares:  7,098,741
Average volume:  35,991
Market cap:   $13,913,532
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Valuation   (See tab for details)
PE ratio:   -0.54
PB ratio:   0.24
PS ratio:   27.83
Return on equity:   -67,395.09%
Net income %:   -6,247,578.60%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy